| Market Capitalization (Millions $) |
1,936 |
| Shares
Outstanding (Millions) |
135 |
| Employees |
156 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-394 |
| Cash Flow (TTM) (Millions $) |
244 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Compass Pathways Plc is a UK-based pharmaceutical company focused on the development of innovative therapies for mental health patients. The company was founded in 2016 and is headquartered in London, UK. Compass Pathways is a leader in the field of psychedelic-assisted therapy, a promising new approach to the treatment of depression and other mental health disorders using psychedelic compounds.
The company's flagship product is a synthetic form of psilocybin, the psychoactive compound found in magic mushrooms. Compass Pathways has completed a phase 2 clinical trial of this product in patients with treatment-resistant depression, and is currently planning to initiate a phase 3 trial. The company is also pursuing other drug development programs, including a proprietary formulation of ketamine.
Compass Pathways has a highly experienced management team, led by co-founder and CEO George Goldsmith. The company has a strong financial position, with over $150 million in funding from investors, including the venture arms of tech giants like Peter Thiel, Bill Gates, and Jeff Bezos. In 2020, the company went public on the Nasdaq stock exchange with a valuation of over $1 billion.
Compass Pathways is committed to scientific rigor and safety in the development of psychedelic-assisted therapies. The company has formed partnerships with leading academic institutions and research organizations to conduct trials and gather data on the safety and efficacy of these therapies. Compass Pathways is also focused on building a sustainable business model that ensures broad access to these therapies for patients in need.
Overall, Compass Pathways is a pioneering company in the emerging field of psychedelic-assisted therapy, with a bold vision for improving mental health outcomes through innovative drug development and clinical research.
Company Address: 33 Broadwick Street London 0
Company Phone Number: 676-6461 Stock Exchange / Ticker: NASDAQ CMPS
|
1.76% 